Orchestra BioMed Holdings, Inc. (OBIO)
NASDAQ: OBIO · Real-Time Price · USD
4.400
-0.280 (-5.98%)
At close: Dec 5, 2025, 4:00 PM EST
4.470
+0.070 (1.59%)
After-hours: Dec 5, 2025, 4:47 PM EST
Orchestra BioMed Holdings Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 2.82 | 2.64 | 2.76 | 3.53 | -0.78 | 5.7 |
| Revenue Growth (YoY) | 6.46% | -4.42% | -21.88% | - | - | - |
| Cost of Revenue | 0.2 | 0.2 | 0.19 | 0.21 | 0.2 | 0.15 |
| Gross Profit | 2.62 | 2.43 | 2.57 | 3.32 | -0.98 | 5.56 |
| Selling, General & Admin | 25.53 | 23.93 | 20.26 | 14.03 | 7.93 | 10.83 |
| Research & Development | 52.33 | 42.8 | 33.82 | 21.95 | 12.89 | 13.48 |
| Operating Expenses | 77.86 | 66.74 | 54.08 | 35.98 | 20.82 | 24.31 |
| Operating Income | -75.24 | -64.3 | -51.51 | -32.66 | -21.8 | -18.75 |
| Interest Expense | -0.68 | -0.3 | -1.4 | - | -0.93 | - |
| Interest & Investment Income | 0.82 | 3.65 | 5.25 | 0.05 | - | 0.33 |
| Other Non Operating Income (Expenses) | - | -0.01 | -0.29 | -1.35 | 0.7 | -0.18 |
| EBT Excluding Unusual Items | -75.1 | -60.96 | -47.95 | -33.96 | -22.03 | -18.6 |
| Gain (Loss) on Sale of Investments | - | -0.07 | -0.02 | 1.03 | -0.99 | -2.75 |
| Other Unusual Items | - | - | -1.15 | -0.68 | - | - |
| Pretax Income | -75.1 | -61.02 | -49.12 | -33.61 | -23.01 | -21.36 |
| Net Income | -75.1 | -61.02 | -49.12 | -33.61 | -23.01 | -21.36 |
| Net Income to Common | -75.1 | -61.02 | -49.12 | -33.61 | -23.01 | -21.36 |
| Shares Outstanding (Basic) | 42 | 37 | 33 | 15 | 2 | 2 |
| Shares Outstanding (Diluted) | 42 | 37 | 33 | 15 | 2 | 2 |
| Shares Change (YoY) | 15.74% | 10.82% | 121.67% | 609.97% | 4.86% | - |
| EPS (Basic) | -1.80 | -1.66 | -1.48 | -2.24 | -10.90 | -10.61 |
| EPS (Diluted) | -1.80 | -1.66 | -1.48 | -2.24 | -10.90 | -10.61 |
| Free Cash Flow | -60.79 | -50.85 | -46.21 | -29.88 | -19.7 | -26.72 |
| Free Cash Flow Per Share | -1.46 | -1.38 | -1.39 | -1.99 | -9.33 | -13.27 |
| Gross Margin | 93.01% | 92.27% | 93.26% | 94.03% | - | 97.46% |
| Operating Margin | -2669.91% | -2437.49% | -1866.16% | -924.34% | - | -328.81% |
| Profit Margin | -2665.05% | -2313.27% | -1779.71% | -951.26% | - | -374.45% |
| Free Cash Flow Margin | -2157.31% | -1927.48% | -1674.09% | -845.74% | - | -468.56% |
| EBITDA | -74.91 | -63.99 | -51.22 | -32.44 | -21.62 | -18.62 |
| D&A For EBITDA | 0.33 | 0.31 | 0.29 | 0.22 | 0.18 | 0.14 |
| EBIT | -75.24 | -64.3 | -51.51 | -32.66 | -21.8 | -18.75 |
| Revenue as Reported | 2.82 | 2.64 | 2.76 | 3.53 | -0.78 | 5.7 |
Source: S&P Capital IQ. Standard template.
Financial Sources.